Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About Chengdu Miaoji

Chengdu Miaoji Headquarter Location

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Chengdu Miaoji News

Gracell Biotechnologies Completes $85M in Series B Funding

Feb 25, 2019

Gracell Biotechnologies, Co., Ltd., a Suzhou, China-based innovative biomedical company, completed an $85m Series B funding. The round was led by Temasek with participation from Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji. The company intends to use the funds to enter clinical trials with several of its next generation immune cell gene therapy drug candidates. Founded by Dr. Wei (William) Cao in 2017, Gracell Biotechnologies is committed to developing low-cost cellular drugs. The company has completed pre-clinical development of a series of low-cost CAR-T products and entered clinical research through Institutional Review Board (IRB) studies. Other products under development include CAR-T cell products developed on its FasTTM CAR technology, Dual-CAR technology, off-the-shelf CAR-T products, and CAR-T products for the treatment of refractory solid tumors. Over the past year, the team has advanced a series of innovative CAR-T products toward clinical research, obtaining valuable data and gaining support from international investors. Gracell expects to develop a data package from its clinical IRB studies and advance several products to IND filing and clinical trials in the near future. The company, which has additional locations in Shanghai and Hong Kong, was initially supported by series A financing from 6 Dimensions shortly after its establishment. FinSMEs

Chengdu Miaoji Investments

1 Investments

Chengdu Miaoji has made 1 investments. Their latest investment was in Gracell Bio as part of their Series B on February 2, 2019.

CBI Logo

Chengdu Miaoji Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/25/2019

Series B

Gracell Bio

$85M

Yes

17

Date

2/25/2019

Round

Series B

Company

Gracell Bio

Amount

$85M

New?

Yes

Co-Investors

Sources

17

Chengdu Miaoji Portfolio Exits

1 Portfolio Exit

Chengdu Miaoji has 1 portfolio exit. Their latest portfolio exit was Gracell Bio on January 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/8/2021

IPO

$99M

Public

1

Date

1/8/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.